# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and a...
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rat...
RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating and annou...
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibo...
TD Cowen analyst Yaron Werber initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating.
Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanco...
Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $80 price target.
Highlights for 2023 and Recent Weeks Successfully completed an underwritten offering of 3,900,000 shares of its common stock...